Computed tomography surveillance scanning after lung cancer surgery: Mathematical optimization of scanning interval based on tumour biology

Interactive Cardiovascular and Thoracic Surgery

Volumn 18, Issue 2, 2014, Pages 149-152

  Poullis, Michael ^a  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

CT scanning; Lung cancer

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; FOLLOW UP; LUNG CANCER; MATHEMATICAL COMPUTING; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RADIODIAGNOSIS; RADIOLOGICAL PARAMETERS; SCANNING INTERVAL; TUMOR GROWTH; TUMOR VOLUME;

CT SCANNING; LUNG CANCER;

CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOPLASMS, SECOND PRIMARY; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84892941771     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivt449     Document Type: Article

References (17)

1. Moore S, Corner J, Haviland J, Wells M, Salmon E, Normand C et al. Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ 2002;325:1145.
2. Goulart BH, Bensink ME, Mummy DG, Ramsey SD. Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw 2012;10:267-75.
3. Diederich S, Wormanns D, Semik M, Thomas M, Lenzen H, Roos N et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 2002;222:773-81.
4. Diederich S, Thomas M, Semik M, Lenzen H, Roos N, Weber A et al. Screening for early lung cancer with low-dose spiral computed tomography: results of annual follow-up examinations in asymptomatic smokers. Eur Radiol 2004;14:691-702.
5. MacRedmond R, McVey G, Lee M, Costello RW, Kenny D, Foley C et al. Screening for lung cancer using low dose CT scanning: results of 2 year follow up. Thorax 2006;61:54-6.
6. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL et al. CT Screening for lung cancer: five-year prospective experience. Radiology 2005;235:259-65.
7. Yumuk PF, Mohammed N, Maat AP, Fink C, Marchal B, O'Brien ME. How do lung cancer specialists follow their patients with stage III non-small cell lung cancer (NSCLC) after definitive treatment? A short report. Eur J Cancer 2012;48:2163-5.
8. Arai T, Kuroishi T, Saito Y, Kurita Y, Naruke T, Kaneko M. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol 1994;24:199-204.
9. Harris K, Khachaturova I, Azab B, Maniatis T, Murukutla S, Chalhoub M et al. Small cell lung cancer doubling time and its effect on clinical presentation: a concise review. Clin Med Insights Oncol 2012;6:199-203.
10. Heuvelmans MA, Oudkerk M, de Bock GH, de Koning HJ, Xie X, van Ooijen PM et al. Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces falsepositive referrals. Eur Radiol 2013;23:1836-45.
11. Honda O, Johkoh T, Sekiguchi J, Tomiyama N, Mihara N, Sumikawa H et al. Doubling time of lung cancer determined using three-dimensional volumetric software: comparison of squamous cell carcinoma and adenocarcinoma. Lung Cancer 2009;66:211-7.
12. Kanashiki M, Tomizawa T, Yamaguchi I, Kurishima K, Hizawa N, Ishikawa H et al. Volume doubling time of lung cancers detected in a chest radiograph mass screening program: comparison with CT screening. Oncol Lett 2012; 4:513-6.
13. Poullis M, Littler J, Gosney J. Biology of colorectal pulmonary metastasis: implications for surgical resection. Interact CardioVasc Thorac Surg 2012; 14:140-2.
14. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Tazelaar HD et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology 2007; 242:555-62.
15. Revel MP, Merlin A, Peyrard S, Triki R, Couchon S, Chatellier G et al. Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. AJR Am J Roentgenol 2006; 187:135-42.
16. Wilson DO, Ryan A, Fuhrman C, Schuchert M, Shapiro S, Siegfried JM et al. Doubling times and CT screen-detected lung cancers in the Pittsburgh Lung Screening Study. Am J Respir Crit Care Med 2012;185:85-9.
17. Colt HG, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2013;143:e437S-54S.